Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

University of Oxford

Thumbnail
July 21, 2020

Novavax keeps investors waiting

Those wanting to see whether the US government was right to give Novavax $1.6bn two weeks ago will have to wait a little longer.

Thumbnail
July 20, 2020

Covid-19 vaccine contest turns to T-cell responses

The coronavirus vaccine race now features three front runners with clinical data, and at least one boasts impressive T-cell responses.

Article image
Vantage logo
July 20, 2020

Synairgen joins the 2020 coronavirus winners club

A small trial of inhaled interferon marks a 30-fold increase in Synairgen stock since January, but the endpoints warrant scrutiny.

Article image
Vantage logo
May 21, 2020

Astrazeneca moves to upstage Moderna in Covid-19 vaccines

The UK big pharma group unveils funding and a clinical programme that could overshadow the efforts of its biotech rival.

Article image
Vantage logo
May 19, 2020

Moderna reminds the markets of biotech’s dual purpose

On the back of coronavirus mania, Moderna, a $30bn company heavily funded by the US government, taps investors for $1.3bn.

Article image
Vantage logo
May 01, 2020

Lonza to do the heavy lifting for Moderna’s Covid-19 vaccine

Moderna becomes the latest coronavirus vaccine player to act on the need for a major manufacturing push.

Article image
Vantage logo
April 30, 2020

Astrazeneca joins the Covid-19 vaccine push

Vantage logo
August 29, 2017

ESC 2017 – Merck still won’t Reveal its hand

Vantage logo
October 05, 2016

Sarepta pivots to business development

Vantage logo
September 26, 2014

Adaptimmune series A sets up independent course

Vantage logo
March 16, 2012

Daunting challenge awaits Okairos hep C vaccine

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 11, 2021

Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review

December 10, 2020

Evaluate Vantage 2021 Preview

View more...

Editor's Picks

Vantage logo
February 10, 2021

2020 wins top of the froths for biotech stocks

Vantage logo
October 04, 2018

Biotech flotations remain in high demand

Vantage logo
February 04, 2021

Glaxo’s growth problem

Vantage logo
January 27, 2021

Go or no go? Oncology decisions ahead for the FDA

Vantage logo
February 05, 2021

Pfizer reveals its PD-1 secret

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.